<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656914</url>
  </required_header>
  <id_info>
    <org_study_id>EMS1115</org_study_id>
    <nct_id>NCT02656914</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Irlanda-2 Association on the Treatment of Common Cold</brief_title>
  <official_title>Phase III, National, Multicenter, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy and Safety of Irlanda-2 Association on the Treatment of Common Cold</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical efficacy of the drug associations in
      the treatment of common cold
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind,randomized, multicenter; Maximal experiment duration: 7 days; 03 visits; Safety
      and efficacy evaluation
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Determine efficacy of Irlanda-2-Association in the treatment of common cold symptoms.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated by the adverse events occurrences</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Irlanda-2-Association</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irlanda-2-Association</intervention_name>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
    <arm_group_label>Irlanda-2-Association</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take 10 mL every 12 hours (2x/day), oral route.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant within 48 hours of the onset of common cold symptoms: headache, sneezing,
             sore throat, nasal obstruction, cough, coryza and body pain;

          -  Signed consent.

        Exclusion Criteria:

          -  Patients with any clinically significant disease that, in the investigator opinion,
             can´t participate in the study;

          -  Patients with any laboratory finding or image finding that, in the investigator
             opinion, can´t participate in the clinical trial;

          -  Patients with history of hypersensitivity to any of the formula compounds;

          -  Participation in clinical trial in the year prior to this study;

          -  Patients with vaccine reaction;

          -  Patients who have uncontrolled asthma. However, participants in use of pulmonary
             corticosteroids (alone or in combination with other products) will be allowed if they
             are in stable dose and diagnosed with controlled asthma;

          -  Patients with gastroesophageal reflux, gastric or duodenal ulcer or other serious
             disease of the gastrointestinal tract;

          -  Patients with diabetes mellitus type I and II;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  Patients in use of drugs that can interfere with flu symptoms evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Allergisa</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

